2Taguchi T, Wakui A, Nabeya K, et al. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group [J]. Gan To Kagaku Ryoho, 1992,19(4):483-488.
3Inuyama Y, Miyake H, Horiuchi M, et al. A late phase II clinical study of cis-diammine glycolato platinum, 254-S, for head and neck cancers [J]. Gan To Kagaku Ryoho, 1992,19(6): 871-877.
4Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients[J]. J Clin Oncol, 1994,12:360-367.
5Furuse K, Fukuoka M, Asamoto H, et al. A randomized comparative study of 254-S plus vindesine(VDS) vs. cisplatin (CDDP) plus VDS in patients with advanced non-small cell lung cancer (NSCLC) [J]. Gan To Kagaku Ryoho,1992,19(7):1019-1026.
6Fukuda M, Shinkai T, Eguchi K, et al. Phase II study of (glycolate-O,O′ ) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer [J]. Cancer Chemother Pharmacol,1990,26(6):393-396.
7Yoshioka T, Gamoh M, Shineha R, et al. A new combination chemotherapy with cis-diammine-glycolatoplatinum (Nedaplatin) and 5-fluorouracil for advanced esophageal cancers [J]. Intern Med, 1999, 38(11): 844-848.
2Hagner N, Joerger M. Cancer chemotherapy:targeting folic acid synthesis[ J ]. Cancer Manag Res ,2010,19 (5) :293 - 301.
3Van CE, Oliveirea J. ESMO Guidelines Working Group. Ad- vanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow - up [ J ]. Ann Oncol, 2009,20(4) :61 -65.
4Barni S, Ghidini A, Coinu A, et al. A systematic review of raltitrexed- based first -line chemotherapy in advanced colorectal cancer [ J ]. Anticancer Drugs, 2014, 25 ( 10 ) : 1122 - 1128.
5Liu Y, Wu W, Hang W, et al. Rahitrexed - based chemo- therapy for advanced colorectal cancer[ J]. Clin Res Hepa- tol Gastroenterol,2014,38 (2) : 219 - 225.
6Bozkurt O, Karaca H, Ciltas A, et al. Efficacy and safety of rahitrexed combinations with uracil - tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of anatolian society of medical oncology (ASMO) [ J ]. Asian Pac J Cancer Prey,2014,15 (4) : 1845 - 1849.
8Kim GP, Sargent D J, Mahoney MR, et al. Phase III noninfe- riority trial comparing irinotecan with oxaliplatin, fluoroura-cil,and leucovorin in patients with advanced colorectal car- cinoma previously treated with fluorouracil: N9841 [ J ]. J Clin Oneo1,2009,27(17) :2848 - 2854.
9Shen J, Wang H, Wei J, et al. Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomark- ers for raltitrexed sensitivity in gastric cancer [ J ]. Int J Cancer,2012,131 ( 6 ) :938 - 945.
10Wei J, Costa C, Ding Y, et al. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second - line docetaxel in advanced gastric cancer [ J ]. J Natl Cancer Inst ,2011,103 (20) : 1552 - 1556.